Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial

Evaluating the bioequivalence and safety of liraglutide injection versus Victoza® in healthy Chinese subjects: a randomized, open, two-cycle, self-crossover phase I clinical trial

Background: Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) analog, and its pharmacokinetic and pharmacodynamic properties as a GLP-1 receptor (GLP-1R) agonist make it an important therapeutic option for many patients with type 2 diabetes mellitus. This study compared the bioequivalence a...

Full description

Bibliographic Details
Main Authors: Chao Liu, Hongrong Xu, Fei Yuan, Hanjing Chen, Lei Sheng, Weili Chen, Haisong Xie, Hongmei Xu, Xuening Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Pharmacology
Subjects:
glucagon-like peptide-1
liraglutide
pharmacokinetics
safety
type 2 diabetes
bioequivalence
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1326865/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1326865/full

Similar Items